News & Views | Published:

One shot forward for HIV prevention

Nature Medicine volume 20, pages 241242 (2014) | Download Citation

This article has been updated

The expression of antibodies to protect against an infectious disease can be achieved by the injection into the host of vectors carrying the gene to the relevant antibodies. Here the authors demonstrate the applicability of this technique to protection from HIV in a humanized mouse model, showing this to be a valid route to pursue in vaccine development for humans (pages 296–300).

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 07 May 2014

     In the version of this article initially published, there are two incorrect sentences in the text due to incorrect interpretation of the publication highlighted in this News and Views article. The sentence “The VRC-07 anti–HIV–1 neutralizing IgG in the mucosa seemed high enough to reduce experimental HIV-1 challenge rates among vector-immunized animals by 62.5%” should read “The VRC-07 anti–HIV–1 neutralizing IgG in the mucosa was high enough to reduce experimental HIV–1 challenge rates among vector-immunized animals completely; other less potent antibodies protected less completely.” Also, the sentence “Furthermore, there was detectable depletion of CD4+ T cells in the spleen and gut, indicating that systematic spread of HIV–1 still occurred in animals, despite the presence of neutralizing antibodies in the mucosa at the time of challenge” should not have been included. In addition, the word “spleen” should not have been included in Figure 1. The label “episomally replicating AAV” in the figure should have been “Episomal AAV vector.” The errors have been corrected in the HTML and PDF versions of the article.

References

  1. 1.

    , & Nat. Rev. Immunol. 13, 693–701 (2013).

  2. 2.

    et al. Nature 481, 81–84 (2012).

  3. 3.

    et al. Nat. Med. 15, 901–906 (2009).

  4. 4.

    et al. Nat. Med. 20, 296–300 (2014).

  5. 5.

    & Front. Immunol. 5, 5 (2014).

  6. 6.

    & Front. Immunol. 4, 341 (2013).

  7. 7.

    & N. Engl. J. Med. 370, 495–498 (2014).

  8. 8.

    et al. N. Engl. J. Med. 365, 493–505 (2011).

  9. 9.

    , et al. Sci. Transl. Med. 4, 151ra125 (2012).

  10. 10.

    et al. PLoS Med. 10, e1001511 (2013).

Download references

Author information

Affiliations

  1. Lawrence Corey and M. Juliana McElrath are at the Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

    • Lawrence Corey
    •  & M Juliana McElrath

Authors

  1. Search for Lawrence Corey in:

  2. Search for M Juliana McElrath in:

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Lawrence Corey or M Juliana McElrath.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nm.3503

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing